Dear Microbiology Insider,
There's no debate that the COVID-19 pandemic has spurred strong growth in the market for infectious disease testing. But there are plenty of other reasons -- 10, in fact -- for continued expansion of infectious disease tests in the in vitro diagnostics (IVD) space.
That's according to Bruce Carlson, publisher of Kalorama Information, a sister company of LabPulse.com. Carlson lists the 10 reasons why he expects IVD testing for infectious diseases to continue to grow in years to come in a new article in our Microbiology Community.
Meanwhile, there has been plenty of news recently in the world of microbiology:
- The U.S. Food and Drug Administration (FDA) has approved an over-the-counter assay for detecting COVID-19, respiratory syncytial virus (RSV), and influenza A -- all in a single test.
- A new handheld blood collection device could be useful in detecting COVID-19 antibodies.
- A new point-of-care test for detecting ovarian cancer has received marketing authorization in Europe.
- The FDA issued a warning against the use of a rapid antigen test for SARS-CoV-2 infection.
- Another SARS-CoV-2 test was recalled due to contamination concerns during manufacturing.
- The FDA issued a warning earlier this month about counterfeit over-the-counter COVID-19 tests that are meant to look like tests that have received FDA authorization.
These are just a few of the stories you'll find in your Microbiology Community.